S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
NYSE:GMED

Globus Medical - GMED Stock Forecast, Price & News

$59.57
+0.06 (+0.10%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$59.29
$61.78
50-Day Range
$57.74
$67.54
52-Week Range
$52.60
$81.78
Volume
694,621 shs
Average Volume
606,969 shs
Market Capitalization
$5.93 billion
P/E Ratio
39.98
Dividend Yield
N/A
Price Target
$77.36

Globus Medical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
29.9% Upside
$77.36 Price Target
Short Interest
Healthy
4.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
14.76%
From $2.10 to $2.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.95 out of 5 stars

Medical Sector

24th out of 1,093 stocks

Surgical & Medical Instruments Industry

4th out of 106 stocks

GMED stock logo

About Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Stock News Headlines

Globus Medical Inc - Ordinary Shares - Class A
Could Globus Medical Be the Best Healthcare Stock?
First Week of GMED October 21st Options Trading
Analyst Ratings for Globus Medical
Globus Medical (GMED) Q2 2022 Earnings Call Transcript
Globus Medical Reports Second Quarter 2022 Results
What 5 Analyst Ratings Have To Say About Globus Medical
Globus Medical Inc Class A - Stock Quote GMED
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Company Calendar

Last Earnings
11/04/2021
Today
10/01/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.36
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$62.00
Forecasted Upside/Downside
+29.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$149.19 million
Pretax Margin
19.89%

Debt

Sales & Book Value

Annual Sales
$958.10 million
Cash Flow
$2.80 per share
Book Value
$17.15 per share

Miscellaneous

Free Float
75,223,000
Market Cap
$5.93 billion
Optionable
Optionable
Beta
1.11

Key Executives

  • Mr. David C. Paul (Age 55)
    Co-Founder & Exec. Chairman
    Comp: $23.57k
  • Mr. Daniel T. ScavillaMr. Daniel T. Scavilla (Age 57)
    Pres, CEO & Director
    Comp: $965.17k
  • Mr. Keith W. PfeilMr. Keith W. Pfeil (Age 43)
    Sr. VP & CFO
    Comp: $623.41k
  • Ms. Kelly G. Huller Esq. (Age 50)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $543.02k
  • Mr. Brian J. Kearns (Age 55)
    Sr. VP of Bus. Devel. & Investor Relations
  • Mr. A. Brett Murphy (Age 57)
    Exec. VP of International Sales
  • Mr. Steven M. Payne (Age 51)
    VP & Controller
  • Mr. Mike Reeder
    Exec. Officer
  • Mr. Richard Holifield
    Exec. Officer
  • Mr. John Dowling
    Exec. Officer













GMED Stock - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GMED shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price forecast for 2022?

9 Wall Street analysts have issued 1 year price targets for Globus Medical's shares. Their GMED share price forecasts range from $62.00 to $100.00. On average, they anticipate the company's share price to reach $77.36 in the next year. This suggests a possible upside of 29.9% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2022?

Globus Medical's stock was trading at $72.20 at the beginning of the year. Since then, GMED shares have decreased by 17.5% and is now trading at $59.57.
View the best growth stocks for 2022 here
.

Are investors shorting Globus Medical?

Globus Medical saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 4,840,000 shares, a drop of 7.5% from the August 31st total of 5,230,000 shares. Based on an average daily trading volume, of 607,400 shares, the short-interest ratio is presently 8.0 days.
View Globus Medical's Short Interest
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) released its earnings results on Thursday, November, 4th. The medical device company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.05. The medical device company had revenue of $229.72 million for the quarter, compared to analyst estimates of $228.28 million. Globus Medical had a trailing twelve-month return on equity of 11.81% and a net margin of 15.91%. The company's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.49 earnings per share.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of $2.10-$2.10 for the period, compared to the consensus earnings per share estimate of $2.09. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.02 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $59.57.

How much money does Globus Medical make?

Globus Medical (NYSE:GMED) has a market capitalization of $5.93 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Globus Medical have?

The company employs 2,400 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.

This page (NYSE:GMED) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.